Related Experiment Video

Updated: May 16, 2026

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation
09:05

Transthoracic Speckle Tracking Echocardiography for the Quantitative Assessment of Left Ventricular Myocardial Deformation

Published on: October 20, 2016

Diastolic abnormalities in normal phenotype hypertrophic cardiomyopathy gene carriers: a study using speckle tracking

Floris Kauer1, Bas M van Dalen, Michelle Michels

  • 1Department of Cardiology, The Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands.

Echocardiography (Mount Kisco, N.Y.)
|December 12, 2012
PubMed

Insights

Speckle tracking echocardiography (STE) reveals increased late diastolic mitral annular velocities in genetically affected hypertrophic cardiomyopathy (HCM) subjects without left ventricular hypertrophy. Early diastolic velocities did not differentiate these individuals from controls.

Area of Science:

  • Cardiology
  • Echocardiography
  • Genetics

Background:

  • Tissue Doppler imaging (TDI) for hypertrophic cardiomyopathy (HCM) identification has limitations due to angle-dependency.
  • Speckle tracking echocardiography (STE) offers an alternative for assessing mitral annular velocities.

Purpose of the Study:

  • To evaluate mitral annular velocity abnormalities in genotype-positive, left ventricular hypertrophy-negative (G+/LVH-) HCM subjects using STE.
  • To determine if STE can differentiate G+/LVH- individuals from healthy controls.

Main Methods:

  • Prospective study involving 23 G+/LVH- subjects and 23 healthy controls.
  • All participants underwent STE to assess mitral annular velocities.

Main Results:

  • No significant differences in global peak systolic or early diastolic annular velocities between G+/LVH- and control groups.
  • Global peak late diastolic annular velocity was significantly higher in G+/LVH- subjects compared to controls (P < 0.001).
  • This increase in late diastolic velocity was observed across all six left ventricular walls.

Conclusions:

  • STE confirms increased peak late diastolic annular velocities in G+/LVH- subjects, consistent with prior TDI findings.
  • Early diastolic annular velocities lack the discriminatory power to differentiate G+/LVH- individuals from controls in this cohort.
Abstract

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Assessment of Cardiac Morphological and Functional Changes in Mouse Model of Transverse Aortic Constriction by Echocardiographic Imaging09:05

Assessment of Cardiac Morphological and Functional Changes in Mouse Model of Transverse Aortic Constriction by Echocardiographic Imaging

Published on: June 21, 2016

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...